Pretax income is the income that a company earns before paying income taxes. Innovent Biologics's pretax income for the
six
months ended in Dec. 2023 was HK$-972 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1,252 Mil.
Innovent Biologics's pretax margin was -25.35%.
During the past 8 years, Innovent Biologics's highest Pretax Margin was -18.44%. The lowest was -61972.09%. And the median was -61.87%.
Innovent Biologics Pre-Tax Income Historical Data
The historical data trend for Innovent Biologics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Innovent Biologics's Pre-Tax Income
For the Biotechnology subindustry, Innovent Biologics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Pre-Tax Income falls into.
Innovent Biologics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Innovent Biologics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1,252 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (HKSE:01801) Pre-Tax Income Explanation
Innovent Biologics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 8 years, Innovent Biologics's highest Pretax Margin was -18.44%. The lowest was -61972.09%. And the median was -61.87%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Innovent Biologics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Innovent Biologics (HKSE:01801) Business Description
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01801 has been successfully added to your 